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Abstract
Introduction: Endothelins are involved in tissue inflammation, pain, edema and cell migration. Our genome-wide
microarray analysis revealed that endothelin-1 (ET-1) and endothelin-2 (ET-2) showed a marked up-regulation in
dorsal root ganglia during the acute phase of arthritis. We therefore examined the effects of endothelin receptor
antagonists on the development of arthritis and inflammatory pain in monoarthritic mice.
Methods: Gene expression was examined in lumbar dorsal root ganglia two days after induction of antigen-
induced arthritis (AIA) using mRNA microarray analysis. Effects of drug treatment were determined by repeated
assessment of joint swelling, pain-related behavior, and histopathological manifestations during AIA.
Results: Daily oral administration of the mixed ETA and ETB endothelin receptor antagonist bosentan significantly
attenuated knee joint swelling and inflammation to an extent that was comparable to dexamethasone. In addition,
bosentan reduced inflammatory mechanical hyperalgesia. Chronic bosentan administration also inhibited joint
swelling and protected against inflammation and joint destruction during AIA flare-up reactions. In contrast, the
ETA-selective antagonist ambrisentan failed to promote any detectable antiinflammatory or antinociceptive activity.
Conclusions: Thus, the present study reveals a pivotal role for the endothelin system in the development of
arthritis and arthritic pain. We show that endothelin receptor antagonists can effectively control inflammation, pain
and joint destruction during the course of arthritis. Our findings suggest that the antiinflammatory and
antinociceptive effects of bosentan are predominantly mediated via the ETB receptor.
Introduction
Rheumatoid arthritis (RA) is a systemic disorder of
unknown etiology and is characterized by chronic inflam-
mation and proliferation of the synovial membrane,
angiogenesis, and dysregulation of immune responses,
which lead to progressive destruction of arthritic joints.
A major symptom of RA is chronic recurrent pain, which
results from the activation and sensitization of primary
afferent nociceptors [1]. After sensitization, nociceptive
neurons respond more strongly to mechanical or thermal
stimulation. This process is triggered by a number of
inflammatory mediators, only some of which (including
IL-6, tumor necrosis factor-alpha, bradykinins, and pros-
taglandins) have been studied in detail [1].
Antigen-induced arthritis (AIA) is a well-established
model of experimental arthritis in rodents and shows
many similarities to human RA [2,3]. Whereas granulo-
cyte infiltration and edema formation occur during the
acute phase of AIA, the chronic phase is characterized by
synovitis with infiltration of mononuclear cells into the
synovial tissue, angiogenesis, pannus formation, and car-
tilage and bone erosion. In addition, flare-up reactions
can be triggered in a timely manner in this model. We
have examined gene expression changes in dorsal root
ganglia (DRGs) during the acute phase of AIA. This
approach led to the identification of a large number of
AIA-regulated genes. Among the genes, which showed a
marked upregulation, were several members of the
endothelin system, including ET-1, ET-2, and ETA.
The endothelin system consists of three peptide ligands
(ET-1, ET-2, and ET-3), which bind to two distinct G
protein-coupled receptors designated ETA and ETB [4].
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Whereas ET-1 and ET-2 can bind to ETA and ETB, ET-3
selectively activates ETB receptors [4]. ETA receptors
have been found on small-diameter DRG neurons [5,6].
Activation of these neurons by ET-1 elicits increased
excitability by a rise in intracellular Ca2+ and activation
of voltage-gated Na+ channels [7]. ETB receptors are
expressed mainly in DRG satellite cells and Schwann
cells [5]. It is thought that ETB receptors on these cells
can stimulate prostaglandin E2 synthesis and release
[8,9]. This study was designed to test our hypothesis that
the endothelin system could represent a potential target
for therapeutic intervention in RA. We therefore exam-
ined the effects of endothelin receptor antagonists on the
inflammation and inflammatory pain during the course
of murine antigen-induced arthritis.
Materials and methods
Animals
Experiments were performed on 86 adult female C57BL/6J
mice (age range of 12 to 16 weeks and body weight of 20
to 30 g). Animals were housed in a climate-controlled
room on a 12-hour light/dark cycle with water and stan-
dard rodent chow available ad libitum. Ethical approval
was obtained before the experiments. All experiments
were approved by the Thuringian state authorities and
complied with European Community regulations (86/609/
EEC) for the care and use of laboratory animals.
Antigen-induced arthritis
Animals were immunized by subcutaneous injection of
100 μg of methylated BSA (mBSA) (Sigma-Aldrich, Seelze,
Germany) dissolved in 50 μL of phosphate-buffered saline
(PBS) and emulsified in 50 μL of complete Freund’s
adjuvant (CFA) (Sigma-Aldrich) 21 and 14 days before
induction of AIA. CFA was supplemented with 2 mg/mL
heat-killed Mycobacterium tuberculosis strain H37RA
(Difco, Heidelberg, Germany). In parallel to immunizations,
5 × 108 heat-inactivated Bordetella pertussis germs
(Chiron-Behring, Marburg, Germany) were administered
intraperitoneally. On day 0, mice were briefly anesthetized
with 2.5% isoflurane, and arthritis was induced by injecting
100 μg of sterile mBSA dissolved in 20 μL of PBS into the
right knee joint cavity, leading to the development of severe
acute synovitis associated with subsequent cartilage and
bone erosion in the arthritic joint. Flare-up reactions were
provoked by injecting 100 μg of mBSA dissolved in 20 μL
of PBS on days 21 and 35 of AIA into the right knee joint
cavity.
mRNA microarray analysis
For microarray analysis, mice in the AIA group (n = 3)
were immunized with mBSA and AIA was induced in
the right knee joint. Mice in the control group (n = 3)
were immunized with mBSA but received an injection
of saline into the right knee joint. On day 2 of AIA,
mice were killed by cervical dislocation, and lumbar
DRGs (L3-L5; ipsi- and contralateral) were dissected and
immediately frozen in liquid nitrogen. Successful induc-
tion of AIA was verified by measurement of joint swel-
ling and histopathological examination. Total RNA was
extracted by using RNeasy (Qiagen, Hilden, Germany)
and hybridized onto an Illumina MouseWG-6 version
1.1 Expression BeadChip (Illumina, Inc., San Diego, CA,
USA) at SIRSLab (Jena, Germany). Fold change of
expression was defined as (AIA left - control left)/(AIA
right - control right), which includes a normalization to
controls. All bead types with a P value of less than 0.01
and fold change of at least 5.0 and not more than -5.0
were selected for further examination by using Ingenuity
Pathways Analysis Software (Ingenuity Systems, Inc.,
Redwood City, CA, USA). Microarray data have been
deposited in a public database [10].
Treatment protocol and drugs
Drug treatment was similar to that reported in previous
studies [11,12]. Briefly, mice were allocated to the follow-
ing groups of 10 animals each under randomized condi-
tions: 0.9% saline per os (p.o.), bosentan 100 mg/kg p.o.,
and ambrisentan 10 mg/kg p.o. Bosentan and ambrisen-
tan were dissolved in saline and administered orally in a
volume of 10 mL/kg body weight. Bosentan (RO470203)
was obtained from Actelion (Basel, Switzerland). Ambri-
sentan (LU208075) was provided by Gilead Sciences
(Foster City, CA, USA). Treatment started 2 hours before
induction of AIA and was continued every 24 hours for
the indicated time periods (3, 21, or 42 days). An addi-
tional group received 0.6 mg/kg dexamethasone palmi-
tate (Merckle, Ulm, Germany) by intraperitoneal
injection. Dexamethasone treatment was carried out for
5 days followed by a 2-day pause starting 12 hours before
AIA.
Pain-related behavior and clinical inflammation
measurement
At two time points before AIA induction (baseline) and on
days 1, 3, 7, 14, and 21 of AIA, secondary mechanical
hyperalgesia was determined on ipsi- and contralateral
hindpaws by using a dynamic plantar aesthesiometer (Ugo
Basile, Comerio, Italy). Animals were placed on a mesh
floor and allowed to acclimate to the testing device. Then
an automated blunt filament was directed to the plantar
surface of the paw, and pressure was increased until the
animal withdraws its limb. The weight force needed to eli-
cit this response was read out in grams. In this study, 10 g
were defined as cutoff. Measurements were performed in
triplicate, and means were taken as mechanical hyperalge-
sic thresholds. Secondary thermal hyperalgesia was
assessed at hindpaws with an algesiometer (Ugo Basile) as
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described [2,13]. After acclimation of the animals to the
testing device, three consecutive radiant heat stimuli were
applied to the hindpaws with intervals of at least 1 minute
between stimuli. Mean latencies were calculated and used
as a measure of withdrawal threshold to heat. Stimuli were
applied for a maximum of 10 seconds to prevent tissue
damage. Swelling was assessed on days 0 to 5, 7, 14, and
21 of AIA by measuring the mediolateral diameter of each
knee by means of an Oditest caliper (Kroeplin, Schlüch-
tern, Germany). For each animal and test day, swelling
was calculated by subtracting the diameter of the nonin-
flamed knee from that of the inflamed knee to account for
anatomical knee joint differences between animals.
Histopathological grading of joint inflammation and
destruction
Tissues were obtained immediately after the final testing.
Both knee joints were removed, skinned, fixed in 4% for-
malin, decalcified with 15% EDTA (ethylenediaminete-
traacetic acid) for 5 days or in 7% AlCl3 in 2.1% HCl and
6% formic acid for 48 hours, embedded in paraffin, cut
into 3-μm thick frontal sections, and stained with hema-
toxylin-eosin for microscopic examination. Four sections
from different levels of the knee joint were examined by
an independent observer who was blinded to the treat-
ments and were evaluated according to a histological
scoring system ranging from 0 to 3 (0 = no, 1 = mild, 2 =
moderate, and 3 = severe alterations). The amount of
fibrin exudation and the relative number and density of
granulocytes in synovial membrane and joint space
allowed grading of the acute inflammatory reaction, and
the relative number and density of infiltrating mononuc-
lear leukocytes in the synovial membrane, the degree of
synovial hyperplasia, and the extent of infiltration and
fibrosis in the periarticular structures allowed grading of
chronic inflammation. The extent of damage of the carti-
lage surface and bone structures was also evaluated on a
scale of 0 to 3, where 0 = no damage, 1 = mild destruc-
tion, 2 = moderate destruction, and 3 = severe destruc-
tion of cartilage and bone (extensive area of chondrocyte
death and cartilage destruction and deep invasive bone
erosions) [14].
Statistical analyses
For statistical analyses, SPSS for Windows (version 17.0;
SPSS Inc., Chicago, IL, USA) was used. First, data were
tested for normal distribution by applying the Kolmo-
gorov-Smirnov test. Differences in histopathological
scores for acute inflammation, chronic inflammation,
and joint destruction as well as joint swelling were ana-
lyzed by one-way analyses of variance (ANOVAs) fol-
lowed by post hoc t tests for comparison between
different groups. Measures obtained from different time
points were compared between groups by using repeated
measures ANOVAs with the between-subjects factor
‘group’ (vehicle, bosentan, and ambrisentan) and the
within-subjects factor ‘time’ (baseline and days 1, 3, 7,
14, and 21 after induction of AIA). Post hoc t tests were
used to describe differences between groups at different
time points when ANOVAs revealed a significant main
effect. Significance was accepted for P values of less
than 0.05. P values from post hoc tests are displayed in
Figures 1, 2, 3 whenever multivariate tests show signifi-
cant overall effects.
Results
Effects of endothelin receptor antagonists on antigen-
induced arthritis
We have assessed gene expression changes in lumbar
DRGs during the acute phase of AIA by using transcrip-
tional profiling by genome-wide microarray analysis. Intri-
guingly, three members of the endothelin system - namely
ET-1, ET-2, and ETA - were also strongly upregulated
(Table 1). ETB was also detected during array analysis but
was not regulated (Table 1). The upregulation of ET-1 and
ET-2 was then verified by real-time polymerase chain
reaction (data not shown). We therefore evaluated effects
of the mixed ETA and ETB endothelin receptor antagonist
bosentan and the ETA-selective antagonist ambrisentan on
AIA in mice. Mice received daily oral administrations for
21 days beginning 2 hours before induction of AIA. Knee
joint swelling and pain-related behavior were assessed
repeatedly during the course of AIA (Figure 1a). On days
1 to 5, untreated mice with AIA exhibited pronounced
swelling of the injected knee, which slowly subsided until
day 21 (Figure 1b). Bosentan strongly inhibited joint swel-
ling during the acute phase of AIA (Figure 1b). In contrast,
ambrisentan failed to promote any detectable anti-inflam-
matory effect (Figure 1b). Under these conditions, the
anti-inflammatory activity of bosentan was similar to that
observed after administration of dexamethasone (Figure
1c). Untreated mice with AIA also exhibited secondary
thermal hyperalgesia, which was detected as decreased
withdrawal latency to radiant heat (Figure 1d). Neither
bosentan nor ambrisentan significantly increased latencies
until paw withdrawal at the inflamed side (Figure 1d). In
contrast, repeated application of dexamethasone produced
a detectable inhibition of thermal hyperalgesia (Figures
1e). Untreated mice with AIA also exhibited secondary
mechanical hyperalgesia, which was detected as decreased
withdrawal threshold to mechanical stimuli (Figure 1f).
Like mice treated with dexamethasone, bosentan-treated
mice showed significantly increased mechanical thresholds
at the inflamed side (Figure 1f,1g). These findings indicate
that the mixed ETA and ETB endothelin receptor antago-
nist bosentan elicits robust anti-inflammatory and antino-
ciceptive responses in monoarthritic mice, whereas the
ETA-selective antagonist ambrisentan failed to promote
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Figure 1 Effects of bosentan and ambrisentan on antigen-induced arthritis (AIA). (a) Schematic drawing of experimental setup. Animals
were immunized 21 and 14 days before induction of AIA. Mice received repeated oral applications of 100 mg/kg bosentan, 10 mg/kg
ambrisentan, or saline (Control) every 24 hours beginning 2 hours before induction of AIA. Dexamethasone was given intraperitoneally (i.p.) at a
dose of 0.6 mg/kg for 5 days beginning 12 hours before induction of AIA. Joint swelling and pain-related behavior were assessed as indicated.
All animals were tested twice during the immunization procedure to obtain baseline values depicted as day 0. (b) Inhibition of knee joint
swelling by bosentan but not by ambrisentan. Knee joint swelling as an indicator of inflammation was assessed by measuring the mediolateral
diameter of each knee. (c) Inhibition of knee joint swelling by dexamethasone. (d) Lack of inhibition of thermal hyperalgesia by bosentan or
ambrisentan. Thermal hyperalgesia was determined with an algesiometer and calculated as reduced withdrawal threshold to heat. (e) Inhibition
of thermal hyperalgesia by dexamethasone. (f) Inhibition of mechanical hyperalgesia by bosentan but not by ambrisentan. Mechanical
hyperalgesia was determined on ipsi- and contralateral hindpaws by using a dynamic plantar aesthesiometer. The weight force needed to elicit
a response was read out in grams. (g) Inhibition of mechanical hyperalgesia by dexamethasone. Values in (b-e) are means ± standard error of
the mean. The results from two-way analysis of variance followed by the Bonferroni post hoc test are shown (*P < 0.05; ο, not significant). p.o.,
per os (by mouth).
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any detectable anti-inflammatory or antinociceptive
activity.
Effect of bosentan on antigen-induced arthritis flare-up
reactions
Given the potent anti-inflammatory and antinociceptive
activity of bosentan during a single induction of AIA,
we asked whether bosentan could protect against
repeated induction of AIA. Mice received oral adminis-
tration of bosentan every 24 hours for 42 days beginning
2 hours before the initial induction of AIA. AIA flare-up
reactions were provoked 21 and 35 days later by injec-
tion of mBSA into the knee joint cavity. Knee joint swel-
ling was assessed repeatedly during the course of AIA
(Figure 2a). As depicted in Figure 2b, untreated mice
responded with a pronounced increase in joint swelling
during each AIA flare-up reaction. Bosentan signifi-
cantly inhibited joint swelling during each of these flare-
up reactions (Figure 2b). Weight loss or any other easily
detectable unwanted drug effects were not noted during
the 42-day treatment period. As shown in Figure 3,
bosentan also potently suppressed histopathological
manifestations of acute and chronic inflammation
detected 3 days after AIA induction as well as inflam-
mation and joint destruction during AIA flare-up
reactions.
Discussion
In an effort to examine gene expression changes during
experimental arthritis, we found that three members of
the endothelin system - namely ET-1, ET-2, and ETA -
were markedly upregulated during the acute phase of
AIA. This is in line with previous findings showing that
patients with RA exhibit increased ET-1 serum levels as
well as high ET-1 concentrations in synovial fluid
[15-17]. Moreover, it is widely accepted that endothelins
Figure 2 Effect of bosentan on antigen-induced arthritis (AIA) flare-up reactions. (a) Schematic drawing of experimental setup. Animals
were immunized 21 and 14 days before induction of AIA. Mice received repeated oral applications of either 100 mg/kg bosentan or saline
(Control) every 24 hours for 42 days beginning 2 hours before the initial induction of AIA. AIA flare-up reactions were provoked on days 21 and
35. Joint swelling was assessed as indicated. All animals were tested twice during the immunization procedure to obtain baseline values
depicted as day 0. After 3, 21, or 42 days, mice were killed, and affected knee joints were prepared for histological scoring. (b) Inhibition of knee
joint swelling by bosentan during AIA flare-up reactions. Knee joint swelling as an indicator of inflammation was assessed by measuring the
mediolateral diameter of each knee. Values in (b) are means ± standard error of the mean. The results from two-way analysis of variance
followed by the Bonferroni post hoc test are shown (*P < 0.05; ο, not significant). p.o., per os (by mouth).
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induce hypernociception in rodents [18-22]. So far, stu-
dies investigating the role of endothelins in the patho-
physiology of arthritis are sparse [18,23,24]. It has been
shown, however, that local administration of endothelin
receptor antagonists reduces edema, neutrophil infiltra-
tion, and production of inflammatory mediators
[21,25-32].
Given the availability of potent endothelin receptor
antagonists, we investigated the effects of systemic
administration of the mixed ETA and ETB endothelin
receptor antagonist bosentan and the ETA-selective
antagonist ambrisentan on pain-related behavior, inflam-
mation, and histopathological manifestations during the
course of AIA. We found that daily oral administration
of bosentan significantly attenuated knee joint swelling.
In contrast, ambrisentan failed to promote any detect-
able anti-inflammatory activity. These findings indicate
that the anti-inflammatory effects of bosentan are
mediated predominantly via the ETB receptor.
Bosentan selectively inhibited mechanical hyperalgesia
but not thermal hyperalgesia. Acute and chronic models
of joint inflammation reliably produce mechanical
hyperalgesia. In some arthritic models, thermal hyperal-
gesia can also be observed; however, it is not known to
what extent thermal hyperalgesia is important in
humans. Interestingly, intradermal injection of ET-1
induces mechanical hyperalgesia in humans, whereas
thermal hyperalgesia could not be observed. Moreover,
previous findings revealed different contributions of ETA
and ETB receptors to thermal and mechanical hyperal-
gesia, respectively [2,9,21,25,28,29,31-34]. Whereas ETA
receptors have been shown to mediate ET-1-induced
thermal hyperalgesia, ETB receptors have been linked to
mechanical hyperalgesia [2,9,21,25,28,29,31-34]. Both
ambrisentan and bosentan had no effect on thermal
hyperalgesia. In contrast, dexamethasone produced a
significant inhibition of thermal hyperalgesia, suggesting
that mechanisms in addition to an upregulation of ET-1
or ET-2 may contribute to the development of thermal
hyperalgesia in our AIA model. At present, we do not
know whether ETB-selective antagonists could exert
therapeutic effects similar to those of mixed ETA and
ETB receptor antagonists. Nevertheless, daily oral bosen-
tan administration was well tolerated over the 42-day
treatment period in our murine AIA model.
To assess gene expression changes in lumbar DRGs
during the acute phase of AIA, we used transcriptional
profiling by genome-wide microarray analysis. Our
results indicate that an acute peripheral inflammation
of the knee joint induces robust changes in gene
expression patterns in DRGs, suggesting that dynamic
adaptations occur in primary sensory neurons in
response to peripheral inflammation. However, this
approach is based on the isolation of total mRNA from
DRGs and, hence, cannot differentiate between mRNAs
originating from neurons, glial cells, endothelial cells,
or infiltrating leukocytes. Nevertheless, we detected a
total of 451 AIA-regulated genes, 436 of which were
upregulated (fold change of at least 5) and only 15 of
which were downregulated (fold change of not more
than -5) in DRGs from the affected side in comparison
with the contralateral side and control animals. Table
1 shows a selection of upregulated genes. This selec-
tion includes regulatory peptides (for example, secretin,
peptide YY, and guanylin) as well as chemokines,
receptors, enzymes, and carriers. Several of these
genes, including phospholipase A2, kallikrein, IL-18,
and CX3CL1, have been associated with arthritis or
inflammatory pain.
Figure 3 Effect of bosentan on histopathological manifestations
of antigen-induced arthritis (AIA). (a) Mice were killed 3 days after
induction of AIA. (b) Mice were killed at day 42 after repeated
induction of AIA. Affected knee joints were prepared for histological
scoring. Four sections per knee joint were examined by an observer
who was blinded to the treatments and were scored according to a
three-parameter scoring system as described in Materials and
methods. Values are means ± standard error of the mean. The results
from two-way analysis of variance followed by the Bonferroni post
hoc test are shown (*P < 0.05).
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Conclusions
We identify the endothelin system as a potential tar-
get for therapeutic intervention in RA by mRNA
microarray analysis. We clearly show that chronic
oral bosentan administration inhibits joint swelling,
protects against joint inflammation and destruction,
and reduces mechanical hyperalgesia during AIA
induction and during AIA flare-up reactions. Thus,
our findings on the endothelin system provide proof
of concept that global gene expression profiling can
Table 1 Selected genes that are upregulated in dorsal root ganglia two days after induction of antigen-induced
arthritis as determined by microarray analysis
Illumina ID Gene Synonym Fold change
scl0011829.2_75-S AQP4a Aquaporin 4 9
scl27591.6.1_80-S AREGa Amphiregulin 10
scl27547.3.1_4-S BMP3 Bone morphogenetic protein 3 8
scl26388.10_270-S BTC Betacellulin 5
scl026365.2_7-S CEACAM1 Carcinoembryonic antigen-related cell adhesion molecule 13
scl0023844.2_19-S CLCA3 Ca2+-activated chloride channel 1,724
scl020312.5_187-S CX3CL1a Chemokine (C-X3-C motif) ligand 1 6
scl48937.1.1_21-S CXADR Coxackie and adenovirus receptor 15
scl31983.48.1_26-S DMBT1 Deleted in malignant brain tumors 678
scl44852.5.1_6-S EDN1a Endothelin 1 16
scl25019.5.1_161-S EDN2 Endothelin 2 5
scl15480.1.1_277-S EDNRAa Endothelin receptor A 7
scl45193.8_18-S EDNRB Endothelin receptor B 1
scl0001767.1_56-S FAM3B Family with sequence similarity 3, member B 10
scl43662.2_474-S F2RL1 F2RL1 coagulation factor II receptor-like 1 28
scl48150.3.1_29-S FAM3D Family with sequence similarity 3, member D 18
scl47093.2_645-S GPR20 G protein-coupled receptor 20 22
scl53162.3.1_182-S GPR120 G protein-coupled receptor 120 6
scl0232431.4_71-S GPRC5A G protein-coupled receptor, family C, group 5, member A 62
scl25025.4.1_56-S GUCA2A Guanylin 802
scl016173.8_28-S IL18a Interleukin 18 6
scl49177.8_486-S ILDR1 Ig-like domain-containing receptor 1 26
scl016612.5_71-S KLK1a Kallikrein 1 113
GI_6754459-S KLK1B26 Kallikrein 1-related peptidase b26 112
scl018050.1_7-S KLK1B4 Kallikrein 1-related peptidase b4 127
scl000139.1_0-S KLK1B5 Kallikrein 1-related peptidase b5 302
scl0016619.1_79-S KLK3 Kallikrein 1-related peptidase b27 121
scl49904.15_203-S MEP1A Meprin A, alpha 20
scl48741.4.1_176-S PLA2G4Fa Phospholipase A2 93
scl39519.5.1_59-S PYY Peptide YY 72
scl16482.8_0-S RAB17 Member of RAS oncogene family 9
scl24993.3_35-S RHBDL2 Rhomboid, veinlet-like 2 5
scl22946.3.1_72-S S100A14a S100 calcium-binding protein 55
scl32104.13.1_7-S SCNN1B Na-channel, nonvoltage-gated 1, beta-subunit 7
scl30493.4.19_120-S SCTa Secretin 9
scl20135.8.1_22-S SDCBP2 Syndecan-binding protein (syntenin) 2 41
scl026456.19_173-S SEMA4G Semaphorin 4G 9
scl0020510.2_224-S SLC1A1 Solute carrier family 1, member 1 5
scl32784.15.1_26-S SLC7A9 Solute carrier family 7, member 9 11
scl00226999.1_58-S SLC9A2 Solute carrier family 9, member 2 31
scl00171286.2_214-S SLC12A8 Solute carrier family 12, member 8 16
scl39885.12.1_61-S SLC13A2 Solute carrier family 13, member 2 47
scl47037.12.1_89-S SLC39A4 Solute carrier family 39, member 4 16
scl41202.6.1_16-S SLC46A1a Solute carrier family 46, member 1 5
Genes were annotated by using Illumina (San Diego, CA, USA) and National Center for Biotechnology Information databases. aGenes previously associated with
arthritis or inflammatory pain.
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lead to the identification of novel therapeutic targets
in arthritis.
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